Dan W.  Gladney net worth and biography

Dan Gladney Biography and Net Worth

Mr. Gladney served as President and Chief Executive Officer for the company from November 2015 to April 2019. He remains as Chairman of the Board of Directors, a position held since October 2016. Mr. Gladney joined the Company in November 2015 as President-elect and a member of the board of directors. Prior to joining the Company, Mr. Gladney served as Chairman and Chief Executive Officer of Lanx, Inc., a medical device company focused on developing and commercializing innovative devices for spinal surgery. Prior to joining Lanx, Inc., Mr. Gladney was a Healthcare Operating Partner at Norwest Equity Partners (NEP), where he was responsible for strategic planning, business growth, and corporate governance for NEP portfolio companies, and executing new investment opportunities for the firm. Prior to joining NEP, Mr. Gladney served as President and Chief Executive Officer of several medical device companies including Heart Leaflet Technologies and ACIST Medical Systems, both of which were acquired by The Bracco Group. He also served as Chairman, Chief Executive Officer and President of Complex Technologies, a publicly traded orthopedic and health and wellness electro therapy company. Mr. Gladney currently serves on the Board of Directors of ARIA CV, Inc. and has been a member of a number of other private and public company boards. After the sale of Lanx, Inc., he acted as a private investor and small business consultant.

How old is Dan W. Gladney?

Mr. Gladney is currently 71 years old. There are 5 older executives and no younger executives at ReShape Lifesciences. The oldest executive at ReShape Lifesciences is Dr. Mark B. Knudson Ph.D., Co-Founder and Special Advisor to the CEO, who is 75 years old. Learn More on Dan W. Gladney's age.

How do I contact Dan W. Gladney?

The corporate mailing address for Mr. Gladney and other ReShape Lifesciences executives is 1001 Calle Amanecer, San Clemente CA, 92673. ReShape Lifesciences can also be reached via phone at (949) 429-6680 and via email at [email protected]. Learn More on Dan W. Gladney's contact information.

Has Dan W. Gladney been buying or selling shares of ReShape Lifesciences?

Dan W. Gladney has not been actively trading shares of ReShape Lifesciences in the last ninety days. Most recently, Dan W. Gladney sold 68 shares of the business's stock in a transaction on Friday, September 10th. The shares were sold at an average price of $8,671.00, for a transaction totalling $589,628.00. Learn More on Dan W. Gladney's trading history.

Who are ReShape Lifesciences' active insiders?

ReShape Lifesciences' insider roster includes Barton Bandy (CEO), Dan Gladney (Director), and Thomas Stankovich (CFO). Learn More on ReShape Lifesciences' active insiders.

Dan W. Gladney Insider Trading History at ReShape Lifesciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/10/2021Sell68$8,671.00$589,628.00View SEC Filing Icon  
See Full Table

Dan W. Gladney Buying and Selling Activity at ReShape Lifesciences

This chart shows Dan W Gladney's buying and selling at ReShape Lifesciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ReShape Lifesciences Company Overview

ReShape Lifesciences logo
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $4.46
Low: $4.37
High: $4.46

50 Day Range

MA: $5.38
Low: $4.26
High: $6.62

2 Week Range

Now: $4.46
Low: $4.09
High: $29.00

Volume

3,522 shs

Average Volume

94,104 shs

Market Capitalization

$3.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41